Policy Brief
HIV testing services
December 2016
WHO/HIV/2016.21
Policy Brief.
WHO recommends that pregnant women receive testing for HIV, syphilis and hepatitis B (HBSAg) at least once during pregnancy, preferably in the first trimester.
Dual HIV/syphilis rapid diagnostic tests (RDTs) can be used as the first test for pregnant women as part of antenatal care (...ANC).
These simple tests can be used at the point-of-care and are cost-saving compared to standard testing in ANC. They enable more women to be diagnosed with HIV and syphilis so that they can access treatment and prevent transmission to their children.
more
Results of the first national survey, 2013–2014
Policy Brief
Consolidated Guidelines
Updated 2016
WHO/HIV/2017.05
NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME
A WHO guide to inform & harmonize national & international pandemic preparedness and response
The main updates from the 2013 interim guidance are:
Alignment with other relevant United Nations policies for crisis and emergency management, and
Inclusion of the significant development in re...cent years of the strategies for pandemic vaccine response during the start of a pandemic.
The guide is available in English, Arabic, Chinese, French, Spanish and Russian
more
Policy Note #4: Myanmar Health Systems in Transition Policy Notes Series
Protecting people from financial hardship when they fall ill is one of the two key elements of universal health coverage (UHC). In practice, this means that the majority of health care costs have to be met from government ...revenues so that services are provided free or with a small affordable co-payment. The alternative is to rely on pre-payment through some form of insurance, where risks are pooled across all contributors.
The challenge in Myanmar is that at present neither approach is functioning. Government spending is too low to meet people’s health needs and the proportion of the population covered by insurance is negligible. As a result, families face a stark choice in the event of serious illness: either defer treatment and face the consequences, or incur what can amount to catastrophic expenses and a downward spiral of disinvestment and poverty.
more
The Road Map outlines various strategies which will guide policy makers, development partners, training institutions and service providers in supporting Government efforts towards the attainment of MDGs related to maternal and neonatal health.
This interim guidance to national health authorities and blood transfusion services outlines the steps required to collect convalescent whole blood (CWB) or plasma (CP) from Ebola virus disease (EVD) recovered patients for transfusion to patients with early EVD, as an empirical treatment modality.
...
Document contents:
Guidance on donor selection, screening, donation and handling of blood and plasma units;
guidance on transfusion of convalescent whole blood or plasma;
other considerations.
more
Policy Guidelines for Health Facilities
The checklist is based on efforts by various national and international institutions, including WHO, CDC and UN OCHA. It
identifies 10 key components and tasks for both countries and the international community. This tool establishes timelines
within which to complete tasks of 30, 60 and 90 days r...espectively from the date of issuing this list, based on the priority level.
However, the periods should be redefined by national authorities on the basis of existing regional and national context. (Note:
this checklist will be updated based on the feedback received from countries).
more
WHO Regional Publications, Western Pacific Series No. 23
Reports the findings and recommendations of a working group convened to prepare guidelines for the use of herbal medicines in Western Pacific countries. Addressed to national health authorities, the report responds to the widespread use o...f herbal medicine in this part of the world and the corresponding need for mechanisms to ensure that these products are safe and effective, yet remain broadly accessible. With this need in mind, the report sets out a comprehensive framework for developing national policies designed to control the safety, efficacy, and quality of herbal medicines, manufacturing practices, product registration, and labelling, marketing, and trade.
more